达帕格利弗洛辛在患有Fabry病的CKD患者中的使用
Yuri Battaglia1,2, Nicola Vitturi3, Giacomo Marchi4
1Department of Medicine, University of Verona, Verona, Italy.
Kidney international reports
|February 18, 2026
概括
像达帕格利弗洛辛这样的-葡萄糖共运输体2 (SGLT2) 抑制剂在法布里病 (FD) 中表现有前途. 这项研究发现,达帕格利弗洛辛减少了蛋白尿和慢性病 (CKD) 的FD患者的功能衰退.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知-葡萄糖共运输体2 (SGLT2) 抑制剂可减少蛋白尿和慢性病 (CKD) 中疾病进展的缓慢.
- 关于SGLT2抑制剂对罕见遗传疾病法布里病 (FD) 的影响的数据有限.
- 费布里病患者经常患上白尿性CKD,需要有效的治疗策略.
研究的目的:
- 评估达帕格利弗洛辛在减少白色素尿,蛋白尿和维护患有法布里病和白色素尿性慢性瘤的患者的功能方面的12个月疗效.
- 评估达帕格利弗洛辛对这种特定患者群体估计的淋巴细胞过率 (eGFR) 降低的影响.
主要方法:
- 一项前性多中心研究包括了患有FD和白性CKD的成年患者,这些患者接受了稳定酶替代疗法 (ERT) 或米加拉沙特和最大耐受氨酸-血管新生素系统抑制剂 (RAS-i).
- 给出了10毫克的达帕格利弗洛辛,尿动白蛋白与肌素的比率 (UACR),24小时蛋白尿和eGFR在基线和12个月被测量.
- 统计分析,包括混合效应模型,用于评估治疗效果,并比较eGFR变化.
主要成果:
- 12个月后,达帕格利弗洛辛显著降低了UACR的47.6%,24小时蛋白尿的22.2%.
- 在达帕格利弗洛辛治疗期间,eGFR保持稳定,与治疗前观察到的显著下降形成鲜明对比.
- 在被确定为快速脏进展的9名患者中,有8名患者在达帕格利弗洛辛治疗后每年达到≤3毫升/分钟的eGFR斜率.
结论:
- 达帕格利弗洛辛在患有FD和白性CKD的患者中显著减少了白尿和蛋白尿.
- 这项研究提供了初步证据,表明达帕格利弗洛辛可能有助于稳定功能,并减少该患者群体的EGFR下降.
- 这些发现表明SGLT2抑制剂在控制法布里病中的脏疾病方面具有潜在的治疗作用.
更多相关视频
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
01:28Chronic Kidney Disease III: Interprofessional Care
494
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
494
01:24Chronic Kidney Disease II: Clinical Manifestations
730
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
730
01:25Chronic Kidney Disease I: Introduction
798
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
798
01:11Renal Failure: Dose Adjustments
505
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
505
01:18Chronic Kidney Disease IV: Nursing Management
422
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
422